Research programme: RNA based immunotherapeutics- Rigontec

Drug Profile

Research programme: RNA based immunotherapeutics- Rigontec

Alternative Names: ImOl 200; ImOl 201; Retinoic acid inducible gene I receptor agonists - Rigontec

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigontec
  • Class Gene therapies; Oligonucleotides; RNA; Small molecules
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Viral infections

Most Recent Events

  • 27 Oct 2017 Rigontec has been acquired by Merck & Co
  • 06 Sep 2016 Preclinical trials in Inflammation in Germany (unspecified route)
  • 01 Jan 2014 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top